Does D22.10 require prior authorization?

No, D22.10 does not require prior authorization (high confidence). Covered without prior authorization.

`D22.10`, Melanocytic nevi of unspecified eyelid, including canthus

ICD-10-CM

No Prior Auth Required

Covered without prior authorization (high confidence)

Maintain all documentation in the patient's medical record and make it available to the contractor upon request; every page must be legible and include patient identifiers (complete name, dates of service).
Medical record must include the legible signature of the physician or non-physician practitioner responsible for and providing the care.
The submitted medical record must support the selected ICD-10-CM code(s) and the submitted CPT/HCPCS code must accurately describe the service performed.
Documentation should state whether the block was performed for diagnostic or therapeutic purposes.

Peripheral nerve blocks are covered when they meet the reasonable and necessary requirements specified in LCD L33933.
Molecular assays for the diagnosis of cutaneous melanoma are billable when submitted with the appropriate CPT/PLA code per these coding instructions.
For the myPath Melanoma assay, bill with CPT 81479 for dates of service prior to 2019-07-01.
For the myPath Melanoma assay, bill with proprietary CPT 0090U for dates of service on or after 2019-07-01.
Other molecular assays for cutaneous melanoma may be billed using CPT 81479 only if there is no applicable CPT or PLA code for that assay.
Molecular assays used for the diagnosis of cutaneous melanoma (melanocytic lesions) may be billed when appropriate CPT or PLA codes are reported.

CGS-J15-L39389, MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma

J15

CGS-J18-L39389, MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma

J18

A59261, Billing and Coding: MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma

WPS-J5-L39479, MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma

Ask Backwork about documentation requirements, denial risks, or coverage in your state.